Table 4.
Effect estimates for gestational age and meconium antiretroviral (ARV) concentrations in infants who were exposed continuously during the 2nd and 3rd trimesters
| Meconium ARVa |
N | Proportion with meconium ARV detection |
Gestational Age Median (IQR), days, weeks |
Unadjusted Model Estimateb (95% CI) |
P- value |
Adjusted Model Estimatebc (95% CI) |
P- value |
|---|---|---|---|---|---|---|---|
| 3TC | 128 | 93.8 % | 267 (263.5 – 276) 38.1 (37.6 – 39.4) |
1.27 (0.75, 1.80) | <0.01 | 1.24 (0.71, 1.77) | <0.01 |
| FTC | 145 | 93.8 % | 269 (265 – 276) 38.4 (37.9 – 39.4) |
0.011 (−0.002, 0.024) | 0.10 | 0.007 (−0.005, 0.018) | 0.26 |
| LPV | 67 | 97.0 % | 269 (263 – 274) 38.4 (37.6 – 39.1) |
3.24 (−0.68, 7.16) | 0.10 | 2.55 (−1.28, 6.38) | 0.19 |
| RAL | 21 | 90.5 % | 271 (266 – 276) 38.7 (38.0 – 39.4) |
0.67 (−1.32, 2.65) | 0.49 | 0.50 (−1.43, 2.42) | 0.60 |
| RTVd | 213 | 89.2 % | 269 (264 – 275) 38.4 (37.7 – 39.3) |
0.006 (−0.007, 0.018) | 0.39 | 0.001 (−0.011, 0.013) | 0.83 |
| TFV | 153 | 96.1 % | 269 (264 – 276) 38.4 (37.7 – 39.4) |
1.22 (0.40, 2.05) | <0.01 | 1.04 (0.25, 1.83) | 0.01 |
a
3TC, lamivudine; FTC, emtricitabine; LPV, lopinavir; RAL, raltegravir; RTV, ritonavir; TFV, tenofovir
b
Estimates represent changes in square-root (TFV, 3TC, LPV, RAL) or log10 transformed (FTC, RTV) meconium concentrations for each increase in gestational age day.
c
All models adjusted for maternal HIV RNA at labor and delivery (L&D) >1000 copies/mL.
d
Only boosted RTV considered; 4 unboosted RTV prescription cases excluded.
CI indicates confidence interval